Type II Heparin-Induced Thrombocytopenia: An Underrecognized Cause of Dialysis Catheter Dysfunction-A Case Report

被引:1
作者
Karki, Sailesh [1 ]
Aryal, Binit [1 ]
Mainali, Arjun [1 ]
Uprety, Navodita [1 ]
Panigrahi, Kalpana [2 ]
Adhikari, Samaj [1 ]
机构
[1] Interfaith Med Ctr, Internal Med, Brooklyn, NY 11213 USA
[2] One Brooklyn Hlth, Interfaith Med Ctr, Internal Med, Brooklyn, NY USA
关键词
subcutaneous unfractionated heparin; unfractionated heparin; hypercoagulable state; hypercoagulable; thromboembolic events; dialysis catheter thrombosis; dialysis catheter dysfunction; thrombocytopenia; heparin induced thrombocytopenia (hit); HEMODIALYSIS-PATIENTS; ANTIBODIES;
D O I
10.7759/cureus.41812
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heparin-induced thrombocytopenia (HIT) is categorized into type 1 and type 2. It causes a decrease in platelet count during or shortly after exposure to heparin. Type 1 is mild and has a non-immune mechanism. Type 2 is a hypercoagulable state resulting from anti-heparin platelet factor 4 (PF4) IgG antibodies. These antibodies cause the activation of endothelium and thrombin generation. Type 2 HIT is complicated by life -threatening thromboembolic events such as deep venous thrombosis, pulmonary embolism, and myocardial infarction. HIT remains an under-recognized cause of dialysis catheter dysfunction and thrombosis. We present a case of a 66-year-old male with recurrent dialysis catheter thrombosis secondary to Type 2 HIT. Avoiding heparin-based dialysis or switching to non-heparin-based anticoagulation or peritoneal dialysis are the possible management strategies for such patients.
引用
收藏
页数:5
相关论文
共 14 条
  • [1] Heparin induced thrombocytopenia: diagnosis and management update
    Ahmed, I.
    Majeed, A.
    Powell, R.
    [J]. POSTGRADUATE MEDICAL JOURNAL, 2007, 83 (983) : 575 - 582
  • [2] American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia
    Cuker, Adam
    Arepally, Gowthami M.
    Chong, Beng H.
    Cines, Douglas B.
    Greinacher, Andreas
    Gruel, Yves
    Linkins, Lori A.
    Rodner, Stephen B.
    Selleng, Sixten
    Warkentin, Theodore E.
    Wex, Ashleigh
    Mustafa, Reem A.
    Morgan, Rebecca L.
    Santesso, Nancy
    [J]. BLOOD ADVANCES, 2018, 2 (22) : 3360 - 3392
  • [3] Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: A population-based study
    de la Vega, LP
    Miller, RS
    Benda, MM
    Grill, DE
    Johnson, MG
    McCarthy, JT
    McBane, RD
    [J]. MAYO CLINIC PROCEEDINGS, 2005, 80 (08) : 995 - 1000
  • [4] Haemodialysis-related-heparin-induced thrombocytopenia: Case series and literature review
    Gameiro, Joana
    Jorge, Sofia
    Lopes, Jose Antonio
    [J]. NEFROLOGIA, 2018, 38 (05): : 551 - 557
  • [5] Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management
    Hogan, Marie
    Berger, Jeffrey S.
    [J]. VASCULAR MEDICINE, 2020, 25 (02) : 160 - 173
  • [6] Heparin-induced thrombocytopenia in end-stage renal disease: Reliability of the PF4-heparin ELISA
    Kelly, Julie
    Sylvester, Katelyn W.
    Rimsans, Jessica
    Bernier, Thomas D.
    Ting, Clara
    Connors, Jean M.
    [J]. RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2021, 5 (05)
  • [7] Khalid S, 2017, CUREUS J MED SCIENCE, V9, DOI 10.7759/cureus.1428
  • [8] Anti-PF4/heparin antibodies associated with repeated hemofiltration-filter clotting: a retrospective study
    Lasocki, Sigismond
    Piednoir, Pascale
    Ajzenberg, Nadine
    Geffroy, Arnaud
    Benbara, Abdel
    Montravers, Philippe
    [J]. CRITICAL CARE, 2008, 12 (03):
  • [9] Heparin-induced thrombocytopenia
    Lovecchio, F.
    [J]. CLINICAL TOXICOLOGY, 2014, 52 (06) : 579 - 583
  • [10] Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis
    O'Shea, SI
    Sands, JJ
    Nudo, SA
    Ortel, TL
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2002, 69 (01) : 72 - 73